Science
Sara Coca Membribes: Final 9-year Follow-Up of CheckMate214
Sara Coca Membribes/LinkedIn

Sara Coca Membribes: Final 9-year Follow-Up of CheckMate214

Sara Coca Membribes, Clinical Research Fellow to Prof Powles at Barts Health NHS Trust, shared a post on X:

“Final 9-year follow-up of CheckMate214:

  • Sustained OS with NIVO+IPI.
  • Favorable-risk OS trend favors NIVO+IPI (HR 0.80) with higher CRs and more durable responses.
  • RCC-specific survival (HR 0.68) closely paralleled OS (HR 0.69).”

Title: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial

Authors: T.K. Choueiri, L. Albigès, D.F. McDermott, H.J. Hammers, B. Escudier, M. Burotto, E.R. Plimack, C. Porta, S. George, T. Powles, F. Donskov, M.B. Atkins, H. Gurney, C.K. Kollmannsberger, M.-O. Grimm, C. Barrios, D. Castellano, V. Grünwald, Y. Tomita, B.I. Rini, R. Jiang, M. van Kooten Losio, C.-W. Lee, N.M. Tannir, R.J. Motzer

Read the Article

Sara Coca Membribes

Other articles featuring Sara Coca Membribes on OncoDaily.

B. Escudier B.I. Rini C. Barrios C. Porta C.-W. Lee C.K. Kollmannsberger cancer D. Castellano D.F. McDermott E.R. Plimack F. Donskov H. Gurney H.J. Hammers L. Albigès M. Burotto M. van Kooten Losio M.-O. Grimm M.B. Atkins N.M. Tannir OncoDaily Oncology R. J. Motzer R. Jiang S. George Sara Coca Membribes T. K. Choueiri T. Powles V. Grünwald Y. Tomita